This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Vigna, E. Articles by Comoglio, P. M. Search for Related Content PubMed PubMed Citation Articles by Vigna, E. Articles by Comoglio, P. M.

"Active" Cancer Immunotherapy by Anti-Met Antibody Gene Transfer

¹ Laboratory for Gene Transfer and Therapy and ² Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Turin Medical School, Turin, Italy

Requests for reprints: Paolo M. Comoglio, Institute for Cancer Research and Treatment, University of Turin Medical School, Strada Provinciale 142, Turin, Italy. Phone: 39-11-993-3601; Fax: 39-11-993-3225; E-mail: paolo.comoglio{at}ircc.it.

Key Words: cancer target therapy • gene therapy • Met oncogene

Gene therapy provides a still poorly explored opportunity to treat cancer by "active" immunotherapy as it enables the transfer of genes encoding antibodies directed against specific oncogenic proteins. By a bidirectional lentiviral vector, we transferred the cDNA encoding the heavy and light chains of a monoclonal anti-Met antibody (DN-30) to epithelial cancer cells. In vitro, the transduced cells synthesized and secreted correctly assembled antibodies with the expected high affinity, inducing down-regulation of the Met receptor and strong inhibition of the invasive growth response. The inhibitory activity resulted (a) from the interference of the antibody with the Met receptor intracellular processing ("cell autonomous activity," in cis) and (b) from the antibody-induced cleavage of Met expressed at the cell surface ("bystander effect," in trans). The monoclonal antibody gene transferred into live animals by systemic administration or by local intratumor delivery resulted in substantial inhibition of tumor growth. These data provide proof of concept both for targeting the Met receptor and for a gene transfer–based immunotherapy strategy. [Cancer Res 2008;68(22):9176–83]